Organicell appoints Harry Leider, MD, MBA as CEO effective June 21, 2023

Zeo ScientifiX, Inc.

Dr. Leider most recently served as CMO/EVP at Gelesis, gaining FDA approval for Plenity and leading the company through a NYSE IPO.
He previously was CMO/Group VP at Walgreens Boots Alliance, leading clinical programs and health analytics across the Fortune 50.
As CEO, he will lead Organicell, a clinical-stage biopharma developing regenerative therapies from perinatal sources for chronic diseases.
Dr. Leider has over 25 years of healthcare executive experience, including roles at Ameritox, and academic appointments at Johns Hopkins and Harvard.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.